ArticleHepatology communications2025
Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research Network.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ferroptosis in liver biology and diseases.Hepatology communications · 2026Review
- Reduction in Hepatic Phosphatidylcholine Biosynthesis Promotes MASH Through Copper Deficiency.bioRxiv : the preprint server for biology · 2026Article
- Ferroptosis in metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWe previously showed that the pattern of liver biopsy iron staining is associated with metabolic dysfunction-associated steatohepatitis (MASH) severity and fibrosis. The goal of the current study was to further examine the relationships between hepatic iron deposition and disease severity in a large biopsy-proven cohort of nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN).
methodsAdult patients enrolled in the NASH CRN Non-alcoholic Fatty Liver Disease (NAFLD) Database, PIVENS, or FLINT studies from November 2004 to May 2022 were included. Patient demographics, clinical, and laboratory data were compared between patients with different iron deposition patterns. Multivariate logistic regression analysis was performed to identify the relationship between the iron deposition pattern and advanced fibrosis.
resultsA total of 2833 patients were included; 1166 patients (41%) had positive hepatic iron staining. Two hundred seventy-two (9.6%) patients had hepatocellular (HC) iron, 284 (10%) had iron in the reticuloendothelial system (RES), and the remaining (21.4%) had mixed iron deposition. A higher proportion of patients with RES iron had grade 3 steatosis (29%), severe hepatocyte ballooning (47%), severe lobular inflammation (15%), cirrhosis (16%), and definite MASH (71%). On multivariate regression analysis, patients with RES iron had higher odds of advanced fibrosis (adjusted OR: 1.34, 95% CI: 1.11-1.62, p=0.003), while patients with HC iron had lower odds of advanced fibrosis (aOR: 0.68, 95% CI: 0.55-0.83, p<0.001).
conclusionsHepatic iron is common in patients with MASH. Patients with a RES iron pattern have a severe disease, while those with HC iron have milder disease. These data provide insights into the potential role of hepatic iron in the pathogenesis of MASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.